Keeping Track: Approvals For Pfizer's Eucrisa, Vericel's Maci; Submissions From Flexion, AcelRx, Ironshore
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Vertex’s ‘Slow Train To Pain’ R&D Rolls On
Vertex is advancing its sodium channel inhibitor VX-548 to mid-stage trials in the second half of the year as a potential treatment for pain after bunionectomy and abdominoplasty procedures.
Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations
The latest US drug development news and highlights from our Performance Tracker.